BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 29953319)

  • 1. FcγRIIIa-dependent IFN-γ release in whole blood assay is predictive of therapeutic IgG1 antibodies safety.
    Alakhras NS; Qiu J; Rocha GV; Witcher DR; Koester A; You J; Schaer DA; Holmgaard RB; Driscoll K; Willy JA; Malherbe LP
    MAbs; 2018; 10(6):913-921. PubMed ID: 29953319
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of Human FcγR Gene Polymorphisms on IgG-Triggered Cytokine Release: Critical Importance of Cell Assay Format.
    Hussain K; Hargreaves CE; Rowley TF; Sopp JM; Latham KV; Bhatta P; Sherington J; Cutler RM; Humphreys DP; Glennie MJ; Strefford JC; Cragg MS
    Front Immunol; 2019; 10():390. PubMed ID: 30899264
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mechanism of first-dose cytokine-release syndrome by CAMPATH 1-H: involvement of CD16 (FcgammaRIII) and CD11a/CD18 (LFA-1) on NK cells.
    Wing MG; Moreau T; Greenwood J; Smith RM; Hale G; Isaacs J; Waldmann H; Lachmann PJ; Compston A
    J Clin Invest; 1996 Dec; 98(12):2819-26. PubMed ID: 8981930
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Extracorporeal human whole blood in motion, as a tool to predict first-infusion reactions and mechanism-of-action of immunotherapeutics.
    Fletcher EAK; Eltahir M; Lindqvist F; Rieth J; Törnqvist G; Leja-Jarblad J; Mangsbo SM
    Int Immunopharmacol; 2018 Jan; 54():1-11. PubMed ID: 29100032
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development of the first reference antibody panel for qualification and validation of cytokine release assay platforms - Report of an international collaborative study.
    Vessillier S; Fort M; O'Donnell L; Hinton H; Nadwodny K; Piccotti J; Rigsby P; Staflin K; Stebbings R; Mekala D; Willingham A; Wolf B;
    Cytokine X; 2020 Dec; 2(4):100042. PubMed ID: 33458650
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recombinant H22(scFv) blocks CD64 and prevents the capture of anti-TNF monoclonal antibody. A potential strategy to enhance anti-TNF therapy.
    Hristodorov D; Mladenov R; Brehm H; Fischer R; Barth S; Thepen T
    MAbs; 2014; 6(5):1283-9. PubMed ID: 25517313
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enhancement of the antibody-dependent cellular cytotoxicity of low-fucose IgG1 Is independent of FcgammaRIIIa functional polymorphism.
    Niwa R; Hatanaka S; Shoji-Hosaka E; Sakurada M; Kobayashi Y; Uehara A; Yokoi H; Nakamura K; Shitara K
    Clin Cancer Res; 2004 Sep; 10(18 Pt 1):6248-55. PubMed ID: 15448014
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Horse cytokine/IgG fusion proteins--mammalian expression of biologically active cytokines and a system to verify antibody specificity to equine cytokines.
    Wagner B; Robeson J; McCracken M; Wattrang E; Antczak DF
    Vet Immunol Immunopathol; 2005 May; 105(1-2):1-14. PubMed ID: 15797470
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cytokine release assays for the prediction of therapeutic mAb safety in first-in man trials--Whole blood cytokine release assays are poorly predictive for TGN1412 cytokine storm.
    Vessillier S; Eastwood D; Fox B; Sathish J; Sethu S; Dougall T; Thorpe SJ; Thorpe R; Stebbings R
    J Immunol Methods; 2015 Sep; 424():43-52. PubMed ID: 25960173
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The "less-is-more" in therapeutic antibodies: Afucosylated anti-cancer antibodies with enhanced antibody-dependent cellular cytotoxicity.
    Pereira NA; Chan KF; Lin PC; Song Z
    MAbs; 2018 Jul; 10(5):693-711. PubMed ID: 29733746
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An Fc engineering approach that modulates antibody-dependent cytokine release without altering cell-killing functions.
    Kinder M; Greenplate AR; Strohl WR; Jordan RE; Brezski RJ
    MAbs; 2015; 7(3):494-504. PubMed ID: 25933349
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A therapeutic human IgG4 monoclonal antibody that depletes target cells in humans.
    Isaacs JD; Wing MG; Greenwood JD; Hazleman BL; Hale G; Waldmann H
    Clin Exp Immunol; 1996 Dec; 106(3):427-33. PubMed ID: 8973608
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression of human FcgammaRIIIa as a GPI-linked molecule on CHO cells to enable measurement of human IgG binding.
    Armour KL; Smith CS; Clark MR
    J Immunol Methods; 2010 Mar; 354(1-2):20-33. PubMed ID: 20138184
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Selective correlation of interferon-gamma, tumour necrosis factor-alpha and granulocyte-macrophage colony-stimulating factor with immunoglobulin G1 and immunoglobulin G3 subclass antibody in leprosy.
    Hussain R; Kifayet A; Dojki M; Dockrell HM
    Immunology; 1999 Oct; 98(2):238-43. PubMed ID: 10540222
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Induction of mouse IgG2a- and IgG3-dependent cellular cytotoxicity in human monocytic cells (U937) by immune interferon.
    Akiyama Y; Lubeck MD; Steplewski Z; Koprowski H
    Cancer Res; 1984 Nov; 44(11):5127-31. PubMed ID: 6435864
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A whole blood in vitro cytokine release assay with aqueous monoclonal antibody presentation for the prediction of therapeutic protein induced cytokine release syndrome in humans.
    Wolf B; Morgan H; Krieg J; Gani Z; Milicov A; Warncke M; Brennan F; Jones S; Sims J; Kiessling A
    Cytokine; 2012 Dec; 60(3):828-37. PubMed ID: 22986013
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antitumor immune effector mechanisms recruited by phage display-derived fully human IgG1 and IgA1 monoclonal antibodies.
    Huls G; Heijnen IA; Cuomo E; van der Linden J; Boel E; van de Winkel JG; Logtenberg T
    Cancer Res; 1999 Nov; 59(22):5778-84. PubMed ID: 10582699
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of a human whole blood assay for prediction of cytokine release similar to anti-CD28 superagonists using multiplex cytokine and hierarchical cluster analysis.
    Walker MR; Makropoulos DA; Achuthanandam R; Van Arsdell S; Bugelski PJ
    Int Immunopharmacol; 2011 Nov; 11(11):1697-705. PubMed ID: 21689786
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase I study of interleukin 12 with trastuzumab in patients with human epidermal growth factor receptor-2-overexpressing malignancies: analysis of sustained interferon gamma production in a subset of patients.
    Parihar R; Nadella P; Lewis A; Jensen R; De Hoff C; Dierksheide JE; VanBuskirk AM; Magro CM; Young DC; Shapiro CL; Carson WE
    Clin Cancer Res; 2004 Aug; 10(15):5027-37. PubMed ID: 15297404
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunological analysis of the murine anti-CD3-induced cytokine release syndrome model and therapeutic efficacy of anti-cytokine antibodies.
    Nouveau L; Buatois V; Cons L; Chatel L; Pontini G; Pleche N; Ferlin WG
    Eur J Immunol; 2021 Aug; 51(8):2074-2085. PubMed ID: 33945643
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.